4//SEC Filing
Dimension Therapeutics, Inc. 4
Accession 0001104659-15-074204
CIK 0001592288operating
Filed
Oct 28, 8:00 PM ET
Accepted
Oct 29, 6:14 PM ET
Size
9.6 KB
Accession
0001104659-15-074204
Insider Transaction Report
Form 4
Dybbs Michael
Director
Transactions
- Conversion
Series B Preferred Stock
2015-10-27−3,208,711→ 0 total(indirect: See Footnote)→ Common Stock (1,097,745 underlying) - Conversion
Common Stock
2015-10-27+1,097,745→ 1,097,745 total(indirect: See Footnote) - Purchase
Common Stock
2015-10-27$13.00/sh+961,538$12,499,994→ 2,059,283 total(indirect: See Footnote)
Footnotes (2)
- [F1]The Series B Preferred Stock automatically converted into Common Stock, for no additional consideration, on a 2.923-for-1 basis at the closing of the Issuer's initial public offering, and had no expiration date.
- [F2]These securities are held by New Leaf Ventures III, L.P. ("NLV-III") and New Leaf Growth Fund I, L.P. ("NLGF"). New Leaf Venture Associates III, L.P. ("NLVA-III") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III") is the general partner of NLVA-III. New Leaf Growth Associates I, L.P. ("NLGA") is the general partner of NLGF and NLVM-III is the general partner of NLGA. Reporting Person is employed by New Leaf Venture Partners, L.L.C., which is affiliated with the above entities and disclaims beneficial ownership of the shares held by NLV-III and NLGF except to the extent of his pecuniary interests therein if any.
Documents
Issuer
Dimension Therapeutics, Inc.
CIK 0001592288
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001592288
Filing Metadata
- Form type
- 4
- Filed
- Oct 28, 8:00 PM ET
- Accepted
- Oct 29, 6:14 PM ET
- Size
- 9.6 KB